FDA Grants Rare Pediatric Designation to Elraglusib for Ewing Sarcoma

The FDA granted a rare pediatric disease designation to elraglusib (9-ING-41), a novel GSK-3β inhibitor, as a potential therapeutic option for patients with Ewing sarcoma.

Read more: https://www.oncnursingnews.com/view/fda-grants-rare-pediatric-designation-to-elraglusib-for-ewing-sarcoma